Outpatient imaging provider Akumin has selected Lunit’s AI software, INSIGHT DBT, to support its nationwide breast cancer screening services.

The Lynnwood, Washington-based company said the tool will be deployed across its more than 150 fixed imaging sites in the U.S. as part of a broader effort to integrate AI into diagnostic workflows. The rollout will focus on improving efficiency and diagnostic accuracy in digital breast tomosynthesis (DBT), commonly known as 3D mammography.

Akumin’s chief medical officer, Dr. Nasir Siddiqui, said the company chose Lunit’s platform based on its clinical performance and regulatory approvals. “We are very excited to have an AI solution that meets our high standards of clinical excellence and that we believe will make a meaningful difference for the patients we serve, and the radiologists who care for them,” Siddiqui said.
Lunit INSIGHT DBT is FDA cleared for 3D mammography, while its companion tool for 2D imaging, INSIGHT MMG, is also cleared and supported by over 100 peer-reviewed studies. According to Lunit, its AI technology has been implemented in more than 200 imaging centers across the country.

Akumin, which partners with over 1,000 physician groups and health systems, is positioning the move as a response to growing pressure on healthcare providers to expand outpatient diagnostic capacity while facing staffing and infrastructure constraints. The company says its mobile and fixed imaging sites offer an alternative to in-house builds for health systems looking to scale services quickly.

Brandon Suh, CEO of the Seoul-based company, said, “Akumin’s investment in Lunit INSIGHT DBT reflects a strategic, evidence-based approach to solving some of the most pressing challenges in diagnostic imaging.”

Both companies frame the partnership as a way to help radiologists detect cancer earlier while managing growing caseloads.

Artificial Intelligence Homepage